iShares
®
Genomics
Immunology
and
Healthcare
ETF
Schedule
of
Investments
(unaudited)
April
30,
2026
(Percentages
shown
are
based
on
Net
Assets)
1
Schedule
of
Investments
Security
Shares
Value
a
Common
Stocks
Canada
 — 
1
.1
%
AbCellera
Biologics,
Inc.
(a)
(b)
..................
411,289
$
1,706,849
a
China
 — 
2
.4
%
GenFleet
Therapeutics
Shanghai,
Inc.
,
Class
H
(b)
...
345,600
1,922,243
Guangzhou
Innogen
Pharmaceutical
Group
Co.
Ltd.
,
Class
H
(b)
............................
120,200
214,848
Shanghai
Henlius
Biotech,
Inc.
,
Class
H
(b)
(c)
.......
83,900
805,577
Sunshine
Lake
Pharma
Co.
Ltd.
,
Class
H
(a)
(b)
......
190,700
1,001,160
3,943,828
a
Denmark
 — 
3
.2
%
Genmab
A.S.
(b)
..........................
19,182
5,078,942
a
France
 — 
9
.3
%
Ipsen
SA
..............................
42,810
8,407,956
Sanofi
SA
..............................
61,394
5,745,033
Valneva
SE
(a)
(b)
..........................
258,253
705,395
14,858,384
a
Germany
 — 
8
.4
%
Bayer
AG
,
Registered
......................
156,689
7,025,574
BioNTech
SE
,
ADR
(b)
......................
63,153
6,533,178
13,558,752
a
Iceland
 — 
0
.4
%
Alvotech
SA
(a)
(b)
..........................
188,379
629,186
a
Japan
 — 
6
.4
%
Ono
Pharmaceutical
Co.
Ltd.
.................
213,700
3,160,657
Takeda
Pharmaceutical
Co.
Ltd.
...............
214,000
7,154,615
10,315,272
a
South
Korea
 — 
0
.6
%
AbClon,
Inc.
(b)
...........................
27,030
903,674
a
Switzerland
 — 
4
.0
%
Roche
Holding
AG
,
NVS
....................
15,724
6,407,527
a
United
Kingdom
 — 
4
.2
%
GSK
PLC
..............................
252,397
6,617,211
Mereo
Biopharma
Group
PLC
,
ADR
(b)
...........
232,638
62,440
6,679,651
a
United
States
 — 
59
.6
%
Arcus
Biosciences,
Inc.
(a)
(b)
..................
133,599
3,406,774
Caris
Life
Sciences,
Inc.
(a)
(b)
..................
205,671
3,907,749
Corvus
Pharmaceuticals,
Inc.
(b)
...............
102,168
1,551,932
CRISPR
Therapeutics
AG
(a)
(b)
.................
55,336
2,896,286
CytomX
Therapeutics,
Inc.
(a)
(b)
................
228,039
962,325
Design
Therapeutics,
Inc.
(b)
..................
55,761
758,350
Exelixis,
Inc.
(b)
...........................
137,027
6,092,220
Ginkgo
Bioworks
Holdings,
Inc.
(a)
(b)
.............
75,293
636,979
Ideaya
Biosciences,
Inc.
(a)
(b)
..................
149,434
4,348,529
ImmunityBio,
Inc.
(a)
(b)
.......................
589,940
4,188,574
Incyte
Corp.
(b)
...........................
59,291
5,648,654
Intellia
Therapeutics,
Inc.
(a)
(b)
.................
66,593
897,674
Iovance
Biotherapeutics,
Inc.
(a)
(b)
...............
593,884
1,995,450
Janux
Therapeutics,
Inc.
(b)
...................
95,943
1,378,701
Kura
Oncology,
Inc.
(a)
(b)
.....................
150,470
1,328,650
Merck
&
Co.,
Inc.
.........................
60,956
6,655,176
Moderna,
Inc.
(a)
(b)
.........................
219,441
10,081,119
Novavax,
Inc.
(a)
(b)
.........................
264,512
2,096,258
Nuvation
Bio,
Inc.
(b)
.......................
426,642
1,898,557
Ocugen,
Inc.
(a)
(b)
..........................
548,690
949,234
Security
Shares
Value
a
United
States
(continued)
OmniAb,
Inc.,
12.50
Earnout
Shares
(b)
(d)
..........
19,498
$
—
OmniAb,
Inc.,
15.00
Earnout
Shares
(b)
(d)
..........
19,498
—
Pacific
Biosciences
of
California,
Inc.
(a)
(b)
.........
483,024
768,008
Personalis,
Inc.
(a)
(b)
........................
94,670
522,578
Prime
Medicine,
Inc.
(a)
(b)
....................
56,846
201,519
Regeneron
Pharmaceuticals,
Inc.
..............
8,462
5,983,142
Revolution
Medicines,
Inc.
(a)
(b)
................
76,325
10,999,959
Rigel
Pharmaceuticals,
Inc.
(b)
.................
31,513
910,726
Twist
Bioscience
Corp.
(b)
....................
103,936
6,075,059
Verastem,
Inc.
(b)
..........................
116,276
634,867
Vertex
Pharmaceuticals,
Inc.
(b)
................
13,345
5,703,386
Vir
Biotechnology,
Inc.
(b)
....................
167,572
1,711,748
Xencor,
Inc.
(b)
...........................
40,644
484,883
95,675,066
a
Total
Common
Stocks — 99.6%
(Cost:
$
143,614,705
)
................................
159,757,131
a
Rights
United
States
 — 
0
.0
%
Arcellx,
Inc.
CVR
(Expires
04/01/30
)
(a)
(b)
..........
73,059
5,114
a
Total
Rights — 0.0%
(Cost:
$
–
)
........................................
5,114
a
Total
Long-Term
Investments — 99.6%
(Cost:
$
143,614,705
)
................................
159,762,245
a
Short-Term
Securities
Money
Market
Funds
 — 
20
.3
%
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
,
3.83
%
(e)
(f)
(g)
......................
32,603,309
32,613,090
a
Total
Short-Term
Securities — 20.3%
(Cost:
$
32,611,627
)
.................................
32,613,090
Total
Investments
—  119.9%
(Cost:
$
176,226,332
)
................................
192,375,335
Liabilities
in
Excess
of
Other
Assets
—
(
19
.9
)
%
..............
(
31,894,516
)
Net
Assets
—
100.0%
.................................
$
160,480,819
(a)
All
or
a
portion
of
this
security
is
on
loan.
(b)
Non-income
producing
security.
(c)
Security
exempt
from
registration
pursuant
to
Rule
144A
under
the
Securities
Act
of
1933,
as
amended.
These
securities
may
be
resold
in
transactions
exempt
from
registration
to
qualified
institutional
investors.
(d)
Security
is
valued
using
significant
unobservable
inputs
and
is
classified
as
Level
3
in
the
fair
value
hierarchy.
(e)
Affiliate
of
the
Fund.
(f)
Annualized
7-day
yield
as
of
period
end.
(g)
All
or
a
portion
of
this
security
was
purchased
with
the
cash
collateral
from
loaned
securities.
Schedule
of
Investments
(unaudited)
(continued)
April
30,
2026
iShares
®
Genomics
Immunology
and
Healthcare
ETF
2
Derivative
Financial
Instruments
Outstanding
as
of
Period
End
Fair
Value
Hierarchy
as
of
Period
End
Various
inputs
are
used
in
determining
the
fair
value
of
financial
instruments
at
the
measurement
date.
These
inputs
to
valuation
techniques
are
categorized
into
a
fair
value
hierarchy
consisting
of
three
broad
levels
for
financial
reporting
purposes
as
follows:
Level
1
–
Unadjusted
price
quotations
in
active
markets/exchanges
that
the
Fund
has
the
ability
to
access
for
identical
assets
or
liabilities;
Level
2
–
Inputs
other
than
quoted
prices
included
within
Level
1
that
are
observable
for
the
asset
or
liability,
either
directly
or
indirectly;
and
Level
3
–
Inputs
that
are
unobservable
and
significant
to
the
entire
fair
value
measurement
for
the
asset
or
liability
(including
the
Valuation
Committee’s
assumptions
used
in
determining
the
fair
value
of
financial
instruments).
The
hierarchy
gives
the
highest
priority
to
unadjusted
quoted
prices
in
active
markets
for
identical
assets
or
liabilities
(Level
1
measurements)
and
the
lowest
priority
to
unobservable
inputs
(Level
3
measurements).
Accordingly,
the
degree
of
judgment
exercised
in
determining
fair
value
is
greatest
for
instruments
categorized
in
Level
3.
The
inputs
used
to
measure
fair
value
may
fall
into
different
levels
of
the
fair
value
hierarchy.
In
such
cases,
for
disclosure
purposes,
the
fair
value
hierarchy
classification
is
determined
based
on
the
lowest
level
input
that
is
significant
to
the
fair
value
measurement
in
its
entirety.
Investments
classified
within
Level
3
have
significant
unobservable
inputs
used
by
the
Valuation
Committee
in
determining
the
price
for
Fair
Valued
Investments.
Level
3
investments
include
equity
or
debt
issued
by
privately
held
companies
or
funds
that may
not have
a
secondary
market
and/or may
have a
limited
number
of
investors.
The
categorization
of
a
value
determined
for
financial
instruments
is
based
on
the
pricing
transparency
of
the
financial
instruments
and
is
not
necessarily
an
indication
of
the
risks
associated
with
investing
in
those
securities.
For
information
about
the
Fund’s
policy
regarding
valuation
of
financial
instruments,
refer
to
its
most
recent
financial
statements.
The
following
table
summarizes
the
Fund’s
financial
instruments
categorized
in
the
fair
value
hierarchy.
The
breakdown
of
the
Fund’s
financial
instruments
into
major
categories
is
disclosed
in
the
Schedule
of
Investments
above. 
Affiliates
Investments
in
issuers
considered
to
be
affiliate(s)
of
the
Fund
during
the
period
ended
April
30,
2026
for
purposes
of
Section
2(a)(3)
of
the
Investment
Company
Act
of
1940,
as
amended,
were
as
follows:
Affiliated
Issuer
Value
at
07/31/25
Purchases
at
Cost
Proceeds
from
Sale
s
Net
Realized
Gain
(Loss)
Change
in
Unrealized
Appreciation
(Depreciation)
Value
at
04/30/26
  Shares
Held
at
04/30/26
Income
  Capital
Gain
Distributions
from
Underlying
Funds
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
.
$
17,020,058
‌
$
15,593,769
(a)
$
—
‌
$
(
2,200
)
$
1,463
‌
$
32,613,090
‌
32,603,309
‌
$
168,292
(b)
$
—
‌
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
(c)
......
40,000
‌
—
‌
(
40,000
)
(a)
—
‌
—
‌
—
‌
—
‌
3,098
‌
—
‌
$
—
‌
$
(
2,200
)
$
1,463
‌
$
32,613,090
‌
$
171,390
‌
$
—
‌
(a)
Represents
net
amount
purchased
(sold).
(b)
All
or
a
portion
represents
securities
lending
income
earned
from
the
reinvestment
of
cash
collateral
from
loaned
securities,
net
of
collateral
investment
fees,
and
other
payments
to
and
from
borrowers
of
securities.
(c)
As
of
period
end,
the
entity
is
no
longer
held.
Futures
Contracts
Description
Number
of
Contracts
Expiration
Date
Notional
Amount
(000)
Value/
Unrealized
Appreciation
(Depreciation)
Long
Contracts
E-Mini
Health
Care
Select
Sector
Index
.......................................................
4
06/18/26
$
592
$
11,731
Level
1
Level
2
Level
3
Total
Assets
Investments
Long-Term
Investments
Common
Stocks
.........................................
$
112,230,254
$
47,526,877
$
—
$
159,757,131
Rights
................................................
—
5,114
—
5,114
iShares
®
Genomics
Immunology
and
Healthcare
ETF
Schedule
of
Investments
(unaudited)
(continued)
April
30,
2026
3
Schedule
of
Investments
Level
1
Level
2
Level
3
Total
Short-Term
Securities
Money
Market
Funds
......................................
$
32,613,090
$
—
$
—
$
32,613,090
$
144,843,344
$
47,531,991
$
—
$
192,375,335
Derivative
Financial
Instruments
(a)
Assets
Equity
Contracts
...........................................
$
11,731
$
—
$
—
$
11,731
(a)
Derivative
financial
instruments
are
futures
contracts.
Futures
contracts
are
valued
at
the
unrealized
appreciation
(depreciation)
on
the
instrument.
Portfolio
Abbreviation
ADR
American
Depositary
Receipt
CVR
Contingent
Value
Rights
NVS
Non-Voting
Shares
Fair
Value
Hierarchy
as
of
Period
End
(continued)